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The spliceosome is a ribonucleoprotein complex involved in RNA splicing, that is, the removal of non-coding introns from precursor
messenger RNA. (Alternative) Splicing events may play an essential role in tumourigenesis. The recent discovery that the spliceosome
is a target for novel compounds with anticancer activity opens up new therapeutic avenues.
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Most protein-coding genes in our genome are composed of
multiple exons interrupted by introns. The exons are usually
relatively short about 50–250 base pairs, whereas introns are much
larger and can be up to several thousands of base pairs. Together
the exon sequences encode the protein, whereas the introns are
generally non-coding. When a gene is transcribed, exons and
intron sequences are converted into a single precursor messenger
RNA (pre-mRNA). In a process called splicing, the intron
sequences are removed from the pre-mRNA and the exons fused
together resulting in the formation of the mature messenger RNA
(mRNA), which is subsequently capped at its 50 end and
polyadenylated at its 30 end, and transported out of the nucleus
to be translated into protein in the cytoplasm. In general, most
genes give rise to multiple spliced transcripts by alternative
splicing. These transcripts contain different combinations of
exons, and sometimes introns or part thereof, leading to different
mRNA variants and the synthesis of alternative proteins (Figure 1).
The mere existence of alternatively spliced products greatly
increases cellular and organismal complexity and may have
allowed for evolution by producing additional regulation and
diversification of gene function. It is obvious that splicing and
alternative splicing must be tightly regulated and executed in time
and space not to interfere with the normal cellular and organismal
physiology. The spliceosome, an intracellular complex of multiple
proteins and ribonucleoproteins, is the main cellular machinery
guiding splicing. Recently, two natural compounds interfering with
the spliceosome were found to display antitumour activity in vitro
and in vivo. Therefore, it is conceivable that inhibiting the
spliceosome could serve as a novel target for anticancer drug
development (Kaida et al, 2007; Kotake et al, 2007).
SPLICING AND ALTERNATIVE SPLICING: THE ROLE
OF THE SPLICEOSOME
To direct correct processing of pre-mRNA, the intron sequences
contain a number of core splicing signals, notably the conserved
splice-site sequences at their extreme 50 and 30 ends and a
conserved branch point region. The branch point sequence and the
branch point itself, usually an adenosine, are located about 20–40
nucleotides upstream of the 30 splice site. The critical process of
recognising splice sites and the removal of introns and/or exons is
the task of the spliceosome (Staley and Guthrie, 1998; Will and
Lu ¨hrmann, 2001). The spliceosome consists of five non-coding
uridine-rich small nuclear ribonucleoproteins (U snRNPs) and a
multitude of associated proteins, creating a network of RNA–
RNA, RNA–protein and protein–protein interactions (Zhou et al,
2002; Jurica and Moore, 2003) (Figure 2). In fact, well over 200
different splicing factors interacting with the spliceosome have
been identified, and it is clear that much more research is needed
before we fully understand all the intricacies of RNA splicing
(Jurica and Moore, 2003; Wang and Burge, 2008). The various
spliceosome components, in particular, the small nuclear RNPs,
are sequentially recruited to the splice sites. Next, they are
assembled into the spliceosome after which splicing is initiated by
a series of two transesterification reactions producing two ligated
exons and a liberated intron (Staley and Guthrie, 1998; Wang and
Burge, 2008) (Figure 2). Splicing at different locations in the same
pre-mRNA transcript, alternative splicing, enables a gene to
produce variant mature mRNAs, and consequently functionally
different proteins (House and Lynch, 2008). The precise mechanisms
of and/or triggers for alternative splicing are yet unknown. In
higher eukaryotes, like humans, the accuracy of splicing is not
solely dictated by base-pairing interactions of the U snRNPs with
the pre-mRNA. Owing to degeneracy and poor definition of small
splice sites at the end of long introns, splice-site recognition is also
influenced by (i) the coupling of splicing with other processes such
as transcription, (ii) the velocity of the splicing reaction, (iii)
external stimuli, like the presence of growth factors or oxidative
stress and (iv) the three-dimensional structure of pre-mRNA itself
(Tazi et al, 2005b; Disher and Skandalis, 2007; House and Kristen,
2008). In the latter case, the three-dimensional folding of pre-
mRNA determines whether a (in pre-mRNA embedded) splice
regulator will be located in the vicinity of a splice site.
Four regulatory sequence elements have been identified; two
stimulative ones, splicing enhancers located in introns (ISE) or
exons (ESE), and two suppressive ones, splicing silencers located
in introns (ISS) or exons (ESS), respectively (Tazi et al, 2005b;
House and Kristen, 2008 and references therein). The enhancers
generally recruit spliceosome components or splicing factors to a
splice site on pre-mRNA. On the other hand, the splicing silencers
block specific splicing sites; hence interfere with the binding of
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www.bjcancer.comcomponents of the spliceosome with the blocked splice site on
pre-mRNA. These specific exonic and intronic pre-mRNA
sequences are modulated by interactions with non-spliceosomal
nuclear RNA-binding proteins. Both repressing (the heterogenous
nuclear ribonucleoprotein (hnRNP) family) and stimulating (the
serine/arginine (SR) protein family) proteins for these splice
modulators have been identified, both regulating alternative
splicing indirectly (Tazi et al, 2005b; House and Kristen, 2008).
In conclusion, the removal of introns and/or exons has to be
precise and complete, otherwise incorrectly or differently joined
exons yield no mature and functional mRNA, or result in altered
genetic messages with the potential of initiating malignant
behaviour in previous normal cells.
ALTERNATIVE SPLICING AND DISEASE/CANCER
Recent research has revealed that alternatively spliced products
can be linked to various (genetic) diseases and also may play a role
in cancer development (Wang and Burge, 2008). A systematic
approach using large-scale sequencing and splicing-sensitive
microarrays gave for the first time a view of the vast spectrum
of alternative transcripts (Blencowe, 2006; Ben-Dov et al, 2008).
One or more alternatively spliced exons can be found in transcripts
of two-thirds of human genes. In general, the function of the
encoded protein remains unchanged. However, some of the
alternative protein products may display a malignant phenotype
(Blencowe, 2006). Whether alternative splicing is the cause or
result of malignant behaviour in cancer cells remains unclear.
However, as alternative splicing affects most genes, it is likely that
cell cycle control, signal transduction, angiogenesis, motility and
invasion and the metastasis and apoptosis processes that are often
impaired in cancer will be affected (Skotheim and Nees, 2007).
Extensive research indicates that several familial cancer
syndromes are caused by somatic (point) mutations or single-
nucleotide-polymorphisms (SNPs) occurring in splice sites. These
changed splice-site signals may give rise to alternative splice
variants of tumour suppressor genes such as BRCA1, APC, p53,
FHIT and LKB1 and the prostate cancer susceptibility gene, KLF6
(see for a recent review Skotheim and Nees, 2007). Moreover, it has
been shown that splice variants of H-RAS, the enzyme phosphatase
PPR2Cg, CD44v3 (a cell surface glycoprotein), SPN1DN (a deletion
mutant of snRNP-specific nuclear import adapter snurportin 1),
RTVP-1 (in malignant gliomas) and CD44v6 (in various epithelial
cancers) all favour tumourous behaviour in cells (Allemand et al,
2007; Barbier et al, 2007; Rino et al, 2007; Vela et al, 2007). The
increasing number of known non-familial cancers that express
alternatively spliced proteins, each of which may contribute to the
malignant phenotype, provides additional impetus to search for
agents that interfere with alternative splicing and may display an
anticancer potential (Barbier et al, 2007).
Currently, three different approaches to target (alternative)
splicing in cancer are explored. First, one may be able to modulate
alternative splicing by identifying specific splice sites and directly
or indirectly block their use. Alternatively, one may identify and
characterise splice variant products (ie, proteins) that contribute
to the malignant phenotype and determine how they differ from
their normal protein counterparts. Structural differences may then
be used to develop antibodies or small molecules that specifically
target these proteins. A second approach may be the manipulation
of splice modulators, for example, hnRNPs or SR proteins, hereby
indirectly influencing splicing activity. A third approach is based
on the simple notion that malignant cells in general have higher
metabolic rates than normal cells, and consequently have increased
splicing rates and are more prone to splice inhibitors or
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Figure 1 Schematic illustration of transcription, pre-mRNA processing/splicing and translation. A protein-coding gene is transcribed by RNA polymerase II
into pre-mRNA. Subsequently, or already during transcription, non-coding introns are removed in a process called splicing, after which the mature mRNA is
capped and polyadenylated and transported to the cytoplasm where it is translated into protein. Depicted is a gene consisting of four exons interspersed by
three introns. Under normal splicing conditions, exons 1, 3 and 4 are linked together forming the vast majority of mature transcripts (bold black arrow).
Alternative splicing may recombine gene elements into new configurations that may or may not display the activity or characteristics of the original protein.
For example, alternative splicing reactions (grey arrows) can result in the acquirement of an extra exon (exon 2), in the skipping of exons (exon 2 and 3)o r
in an extra exon and part of the first intron through the use of a cryptic splice site in the first intron. In the latter case, a truncated protein may form due to
the presence of a termination codon in the remaining intron sequence. Under normal circumstances, nonsense-mediated decay (NMD) is responsible for
the degradation of mRNAs that have a premature stop codon to prevent the synthesis of detrimental truncated proteins. Note that the NMD is
dysfunctional in cells treated with spliceostatin A leading to the expression of truncated proteins (see text for details).
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cause tumour inhibition at drug levels that do not affect normal
cells.
The three strategies such as (i) splice-site modulation and
targeting of variant proteins; (ii) targeting of splice modulators
and (iii) spliceosome inhibitors are reviewed in detail below.
SPLICE-SITE MODULATION AND TARGETING OF
VARIANT PROTEINS
The delineation of splice sites used in alternative splicing or the
functional characterisation of aberrant proteins expressed as a
result of alternative splicing may provide the necessary insight for
therapeutic interference. Specific splice-site mutations or proteins
might (i) prove to be of predictive value and (ii) become potential
prognostic markers (Yu et al, 2007), (iii) prove to be targets of
future (anticancer) antibody-guided drugs (Orban and Olah, 2003;
Heider et al, 2004; Xiang et al, 2007) or (iv) become a target for
peptide receptor radionucleotide therapy. An example of the latter
is a splice variant of the cholecystokinin receptor found in
colorectal and pancreatic cancer that can be targeted by radio-
nuclide therapy (Laverman et al, 2008). A disease in which an
understanding of the alternative splicing process is used for
therapeutic purposes is Duchenne’s muscular dystrophy (DMD).
Duchenne’s muscular dystrophy is a neuromuscular disease
caused by deletions/duplications or point mutations in the
2.4Mb DMD gene, encoding dystrophin, causing disruption of
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Figure 2 The spliceosome assembly cycle. Through interactions with various proteins that recognise specific splice site features, the spliceosome
components, that is, small nuclear ribonucleoproteins (snRNPs) designated with U1, U2, U4, U5 and U6 are sequentially recruited to the splice site and
assembled into the spliceosome. Once completed, splicing is catalysed in two consecutive transesterification reactions. In the initial step, the 20 OH group of
the branch point adenosine upstream of the 30 end of the intron reacts with the 50 splice junction, forming a novel 20,5 0 phosphodiester bond between the
branch point and the 50 terminal nucleotide of the intron, giving rise to a lariat structure. In the second reaction, the 30 OH of the 50 exon attacks the 30 splice
junction producing linked 50 and 30 exons and liberating the intron. Subsequently, the snRNPs involved are released and recycled in the splicing process. In
the top right-hand corner, a detailed view of U2 snRNP with subcomplexes, SF3a and SF3b, is shown. The spliceosome-associated proteins (SAP) 130
and/or 155 are targeted by pladienolide derivatives (a.o. E-7107) and spliceostatin A.
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circumventing the mutated exon through intramuscular injection
of carefully designed antisense oligonucleotides, corrects the ORF
of dystrophin in in vitro cell lines, animal models and humans (van
Deutekom et al, 2007). Another example concerns spinal muscular
atrophy (SMA) caused by the deletion of SMA1 gene and the
inability of the remaining SMA2 gene, which is virtually identical
to SMA1, to compensate for the SMA1 loss, as its transcript lacks
exon 7. Here, antisense oligonucleotides targeting an intronic
splicing silencer (ISS-N1) may fully restore SMN2 exon 7 inclusion
(Singh, 2007).
If we indeed are able to create therapeutic approaches that
correct the deleterious effects of splice variants by remodelling the
(alternative) splice reactions in non-malignant diseases, it is
conceivable that this approach might also be applicable in
malignancies; Here, splice-site modulation would be a valuable
concept for intervening in the expression of various oncogene and
tumour suppressor gene mutations.
TARGETING OF SPLICE MODULATORS
The SR proteins comprise a family of splice factors that modulate
splice-site selection by mediating the interaction between pre-
mRNA transcripts and the spliceosome. Phosphorylation of the
serines in their arginine/serine (RS) domains regulates the
intracellular localisations of SR proteins and their interaction with
related domains of other splice factors or RNA. This consequently
affects alternative splicing of pre-mRNAs. There are several
kinases, for example, Clk/Sty, SRPK1, SRPK2 and topoisomerase
I that are known to phosphorylate SR proteins. Several compounds
have been reported that target these kinases, for example,
diospyrin (Tazi et al, 2005a), indole derivatives (Soret et al,
2005) and indolocarbazole (NB506; Pilch et al, 2001), inhibit the
kinase activity of topoisomerase I. Similarly, a benzothiazole
compound displayed clear inhibitory effects on the activity of
Clk1/Sty (Muraki et al, 2004). It was shown that exposure to these
compounds modulates the splicing profile of several genes, and
alters gene expression patterns, due to inhibition of SR protein
phosphorylation. In future, drugs like these or derivatives thereof
may be used for the therapeutic manipulation of alternative
splicing.
SPLICEOSOME INHIBITORS
Recently, two chemically different microbial natural products with
profound cancer cell inhibiting potential were found to target the
spliceosome. Both compounds, the pladienolide derivatives
(Kotake et al, 2007) and spliceostatin A (Kaida et al, 2007), appear
to bind to SF3b, a subcomplex of U2 snRNP, which is an essential
component of the spliceosome (Figure 2). SF3b together with SF3a
enable U2 snRNP to associate with the branch point region near
the 30 end of the intron. The SF3b subcomplex consists of seven
proteins such as the spliceosome-associated protein (SAP) 10,
SAP14a, SAP14b, SAP49, SAP130, SAP145 and SAP155. The
binding of pladienolide and spliceostatin A to SF3b causes an
inhibition of the spliceosomal functions resulting in impaired
splicing, and thus altered gene expression patterns.
Pladienolide compounds, in particular pladienolide B and D,
displayed anticancer activity (Mizui et al, 2004; Kotake et al, 2007).
E-7107 is a synthetic urethane derivative of pladienolide D with
activity against tumour cell lines and human tumour xenografts
(Iwata et al, 2004). Treatment of a drug screen panel of 39 cancer
cell lines with pladienolides resulted in profound growth inhibition
with greatest activity against breast and lung cancer cell lines.
Comparison of the pladienolide sensitivity profile to that of other
anticancer agents revealed that pladienolide has a unique and
distinct antitumour spectrum. Additionally, a panel of six cancer
cell lines made resistant against classic cytotoxic compounds such
as camptothecin, etoposide, vincristine, 5-fluorouracil, doxorubi-
cin and cisplatin were just as sensitive to pladienolide as their
drug-sensitive parental cell lines. Although in most cell lines, the
exact mechanism of drug resistance was not known, at least one
cell line overexpresses P-glycoprotein (MDR1 and ABCB1)
implying that pladienolides are not a substrate for this ubiquitous
drug transporter (Mizui et al, 2004). Administration of variable
doses of 2.5–10mgkg
 1day
 1 of pladienolide B for 5 consecutive
days in six human tumour xenograft models, representing breast,
ovarian, colon and prostate cancer, caused dose-dependent growth
inhibition. Moreover, in the breast cancer BSY-1 xenograft, a clear
tumour regression with no sign of recurrence for 36 days was
noted (Iwata et al, 2004; Mizui et al, 2004; Kotake et al, 2007). The
most prominent adverse effects were a reversible weight loss and
dose-limiting haematopoietic toxicity.
By using differently tagged pladienolide derivatives as chemical
probes, it was discovered that pladienolide interacts with SAP130
of the SF3b subcomplex. However, a partial interaction with
additional components of SF3b (SAP145 and SAP155) cannot be
ruled out (Kotake et al, 2007). Although the precise functions of
SAP130, SAP145 and SAP155 within the U2 snRNP are not clearly
defined, it is likely that the activity of SF3b and hence the U2
snRNP is modulated or impaired by pladienolide binding as
indicated by the observed time and dose-dependent disturbance of
in vivo splicing and the associated growth inhibition. Pladienolide
treatment causes an accumulation of unspliced or incompletely
spliced pre-mRNAs and gives rise to fewer and larger nuclear
speckles and intranuclear sites where splice factors are stored.
Similar phenotypes were observed when other spliceosome
components like the U1 and U6 snRNAs were knocked down by
antisense oligonucleotides (Kotake et al, 2007), or when the SF3b
components such as SAP130, SAP145 and SAP155 were down-
regulated by siRNAs (Kaida et al, 2007).
FR901464 and its methylated derivative spliceostatin A also
interact with SF3b, most likely by binding SAP130 or SAP155
(Kaida et al, 2007). Similar to the effects induced by pladienolide,
splicing is partially inhibited causing pre-mRNA to accumulate.
Whereas upon spliceostatin A treatment, most pre-mRNA species
are retained in the nucleus, a subset of unspliced or partially
spliced pre-mRNA is prematurely transported to the cytoplasm
where it is translated into aberrant proteins. These observations
strongly suggest that SF3b is not only involved in splicing but also
in the retention of pre-mRNA. FR901464 and most likely
spliceostatin A are potent anticancer agents affecting the
proliferation of cancer cell lines (Kaida et al, 2007 and references
therein), and inhibiting tumour growth in various xenograft
models (Nakajima et al, 1996). The observation that cells exposed
to FR901464, spliceostatin A and pladienolide showed a cell cycle
arrest in G1 and G2/M phases and prompted a study of the
involvement of cell cycle regulators, including cyclins, cyclin-
dependent kinases (CDKs) and some positive and negative
regulators of these proteins. It was found that cyclin A and CDK
levels were unchanged, whereas p16 and p27, both negative
regulators of CDKs levels, were increased. In addition, a C-
terminally truncated p27 is expressed due to the translation of an
aberrantly spliced p27 pre-mRNA. The truncated p27, however, is
still capable of inhibiting CDK2 and may be partly responsible for
the observed cell cycle arrest, and perhaps the antitumour activity
(Kaida et al, 2007).
Clearly, binding of pladienolide and spliceostatin A to SF3b
components interferes with the splicing process as well as
surveillance mechanisms that are operational in the cell to prevent
the synthesis of truncated proteins. On the basis of the promising
preclinical data with respect to the potential anticancer activity of
pladienolides B and D and E-7107 phase I dose-escalation trials
with E-7107 are currently ongoing in Europe and the United States.
Apart from determining the classic toxicity end points, extensive
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appropriate biomarkers to assess the efficacy of these novel agents.
The detailed analysis of drug-induced changes in gene expression
patterns may give a deeper insight into the mode of action of these
drugs and better define the beneficial effects for cancer patients.
CONCLUSIONS
RNA splicing is an essential and complex cellular process, which is
regulated and mediated by many different factors. Now that our
understanding of the physiology of the spliceosome increases as
well as our perception increases how (alternative) splicing may
contribute to cancer, we hopefully can find ways to control and
intervene with splicing, hereby preventing the expression of
carcinogenic proteins. The pladienolide compounds and spliceo-
statin A that target the spliceosome may very well become the first
representatives of a totally new class of anticancer agents.
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